Liquid-based cytology testing | BD Cervical cancer

Discover BD SurePath™ Liquid-based Pap Test

The BD SurePath™ Liquid-based Pap Test is an FDA and CE-marked cytology method with higher cervical disease detection and a lower unsatisfactory rate compared to conventional cytology and other liquid-based cytology (LBC) devices.¹

Reliable sample
collection

Standardised slide
preparation

Accurate results

Simple and efficient cell collection that ensures sample quality

Visual

The head of the collection device is deposited directly into the BD SurePath™ Collection Vial so 100% of the collected cells are sent to the laboratory for analysis – unlike the rinsing method which can result in up to 37% of cells being discarded.^2,3
The cells are preserved in an ethanol solution for optimal slide preparation in the lab.⁴
The same sample can be used for cytology testing, immunocytochemistry, and HPV testing.^4-6

See how BD SurePath™ can help you to collect cervical samples of high quality for cytology and molecular testing.

Unique and standardised sample processing that offers homogenous slides

BD SurePath™ Liquid-based Pap Test uses a proprietary cell enrichment process to eliminate blood, inflammatory cells, mucus and other debris. Only the most diagnostically relevant material is presented on the slide, offering a clear background.^7,8

Automated slide preparation with on-board staining results in a 13 mm deposition area and uniform distribution of the cells in a thin layer.⁹

Check out the quality of slides obtained with BD SurePath™ Liquid-based Pap Test

Accurate and definitive results that enhance patient care

Women* who are screened with BD SurePath™ Liquid-based Pap Test have a higher chance of having their precancerous lesions detected than women who are screened with either conventional cytology or other LBC devices.²

Compared to conventional cytology, BD SurePath™ Liquid-based Pap Test resulted in:¹
-58% in unsatisfactory reports
-29% in ASC-US/LSIL ratio
+64% in HSIL+ detection
+107% in LSIL+ detection

Decrease unsatisfactory reports

Increase the detection of cervical precancerous lesions

Decrease the risk of cervical cancer in the follow-up period

The BD SurePath™ Liquid-based Pap Test is your trusted partner from sample collection to result reporting.

BD solutions for
HPV testing

Today’s challenges BD Onclarity™ HPV Assay BD SurePath™ Liquid-based Pap Test BD Portfolio Genotype evidence

Shifting to HPV primary screening requires reliable HPV tests

HPV primary screening requires reliable HPV tests

Increasing laboratory pressure calls for versatile instrumentation

Increasing laboratory pressure calls for integrated automation of HPV testing

Reliable triage methods are key

Reliable triage methods are key in HPV primary cervical cancer screening

The importance of self-collection

The importance of self-collection in HPV screening

HPV extended genotyping to improve patient management

BD Onclarity™ HPV Assay offers a reliable DNA-based PCR assay

HPV Assay that gives flexibility in screening paradigm and sample type

HPV Self collection

HPV Self-collection with BD Onclarity™ HPV Assay

HPV testing automation adapted to your needs

BD COR™ System: Comprehensive capabilities, breakthrough performance

Automate cytology from sample to result

Automate cervical cytology from sample to result

Training for pathologists and cytotechnicians

Training for pathologists and cytotechnologists

Fully integrated end-to-end cervical cancer screening solutions

HPV testing solutions

Cytology testing solutions for cervical cancer screening

Extend the power of HPV testing

FDA Clinical Trial

FDA Clinical Trial

Extended genotyping

Assay design

Persistence tracking

Persistence tracking

Diagnostic challenges

ASC-US, atypical squamous cells of undetermined significance; FDA, Food and Drug Administration; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesions; LBC, liquid-based cytology; LSIL, low-grade squamous intraepithelial lesions; Pap, Papanicolaou; SIL, squamous intraepithelial lesions.

1. Fremont-Smith M et al. Cancer. 2004;102(5):269–79.
2. Nance KV. Diagn Cytopathol. 2007;35(3):148–53.
3. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–74.
4. BD SurePath™ Collection Vial Package Insert (500017013).
5. CINtec® PLUS Cytology Kit Package Insert.
6. BD Onclarity™ HPV Assay Package Insert (8089899).
7. Sweeney BJ et al. Cancer Cytopathol. 2006; 108(1): 27–31
8. Kenyon S et al. Cancer Cytopathol. 2010;118(5):244–9.
9. BD Totalys™ SlidePrep Instrument User’s Manual (500005570).
10. Ransdell JS et al. Cancer Cytopathol. 1997;81(3):139–43.
11. Nygård JF et al. J Med Screen. 2004;11(2):70–6.
12. Rozemeijer K et al. BMJ. 2017;356:j504.